Alps Advisors Inc. decreased its holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 5.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,284 shares of the biopharmaceutical company’s stock after selling 1,070 shares during the quarter. Alps Advisors Inc.’s holdings in Vanda Pharmaceuticals were worth $286,000 at the end of the most recent quarter.
A number of other hedge funds have also added to or reduced their stakes in the stock. Pearl River Capital LLC raised its position in Vanda Pharmaceuticals by 6,148.0% during the 1st quarter. Pearl River Capital LLC now owns 6,248 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 6,148 shares during the last quarter. O Shaughnessy Asset Management LLC purchased a new position in Vanda Pharmaceuticals during the 1st quarter worth $117,000. Victory Capital Management Inc. purchased a new position in Vanda Pharmaceuticals during the 1st quarter worth $144,000. BNP Paribas Arbitrage SA raised its position in Vanda Pharmaceuticals by 62,758.8% during the 1st quarter. BNP Paribas Arbitrage SA now owns 10,686 shares of the biopharmaceutical company’s stock worth $197,000 after buying an additional 10,669 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale raised its position in Vanda Pharmaceuticals by 23.3% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 10,600 shares of the biopharmaceutical company’s stock worth $209,000 after buying an additional 2,000 shares during the last quarter.
In other Vanda Pharmaceuticals news, Director Richard W. Dugan sold 15,000 shares of the firm’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $14.85, for a total transaction of $222,750.00. Following the sale, the director now directly owns 50,770 shares of the company’s stock, valued at approximately $753,934.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Timothy Williams sold 2,575 shares of the firm’s stock in a transaction dated Wednesday, August 14th. The stock was sold at an average price of $14.69, for a total transaction of $37,826.75. Following the sale, the senior vice president now directly owns 57,425 shares in the company, valued at $843,573.25. The disclosure for this sale can be found here. 8.20% of the stock is owned by company insiders.
A number of equities analysts have commented on VNDA shares. Citigroup upgraded shares of Vanda Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $19.00 price objective for the company in a research report on Thursday, August 1st. Zacks Investment Research upgraded shares of Vanda Pharmaceuticals from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a research report on Friday, August 2nd. ValuEngine downgraded shares of Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday. Finally, Stifel Nicolaus restated a “hold” rating and set a $17.00 price objective on shares of Vanda Pharmaceuticals in a research report on Wednesday, July 31st. Three analysts have rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company. Vanda Pharmaceuticals has an average rating of “Hold” and a consensus target price of $26.57.
Shares of NASDAQ VNDA opened at $13.65 on Friday. The stock has a market cap of $755.96 million, a price-to-earnings ratio of 28.44 and a beta of 0.39. Vanda Pharmaceuticals Inc. has a 52 week low of $11.83 and a 52 week high of $33.44. The company’s 50-day moving average price is $14.28 and its 200 day moving average price is $15.79.
Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings results on Wednesday, July 31st. The biopharmaceutical company reported $0.21 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.03) by $0.24. Vanda Pharmaceuticals had a net margin of 13.61% and a return on equity of 10.23%. The company had revenue of $59.06 million for the quarter, compared to analysts’ expectations of $54.19 million. During the same period last year, the company earned $0.15 EPS. The firm’s revenue for the quarter was up 24.7% compared to the same quarter last year. On average, analysts predict that Vanda Pharmaceuticals Inc. will post 0.32 earnings per share for the current year.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.
Further Reading: What causes a yield curve to invert?
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.